Skip to main navigation
Investor Relations
Company StatementsMedia ContactEmail Alerts
Events & PresentationsFinancialsStock InformationGovernanceResources
PatientsTeamCommunityEnvironmentCompliance & Transparency
Our LocationsMedical Information
magnifying glass icon
Incyte Home
Main Nav
  • Our Company
  • What We Do
  • Culture & Careers
  • Patient Resources
  • HCP Resources
  • Our Stories
  • Responsibility
  • Our Company
    • Our Leadership
  • What We Do
    • Portfolio
    • Oncology
      • Approved Therapies
      • HCP Resources
    • Dermatology
      • Approved Therapies
      • HCP Resources
    • Partnerships
  • Culture & Careers
    • Open Positions
    • Incyte Involved
    • Inclusion
  • Patient Resources
  • HCP Resources
  • Our Stories
  • Responsibility
    • Patients
    • Team
    • Community
    • Environment
    • Compliance & Transparency
Main Nav
  • magnifying glass icon
  • Our Company
    • magnifying glass icon
    • Our Leadership
  • What We Do
    • magnifying glass icon
    • Portfolio
    • Oncology
    • Dermatology
    • Partnerships
  • Culture & Careers
    • magnifying glass icon
    • Open Positions
    • Incyte Involved
    • Inclusion
  • Patient Resources
  • HCP Resources
  • Our Stories
  • News
    • magnifying glass icon
    • Company Statements
    • Media Contact
    • Email Alerts
  • Investors
    • magnifying glass icon
    • Events & Presentations
    • Financials
    • Stock Information
    • Governance
    • Resources
  • Responsibility
    • magnifying glass icon
    • Patients
    • Team
    • Community
    • Environment
    • Compliance & Transparency
  • Contact Us
    • magnifying glass icon
    • Our Locations
    • Medical Information
  • United States
Home  >  Investors

Incyte International Locations

NORTH AMERICA— HEADQUARTERS

DENMARK

ITALY

SPAIN

UNITED KINGDOM

EUROPE— HEADQUARTERS

FINLAND

JAPAN

SWEDEN

AUSTRIA

FRANCE

THE NETHERLANDS

SWITZERLAND

CANADA

GERMANY

NORWAY

PORTUGAL

Close

Investors

Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.

Quick Links

  • Investor Presentation
  • Responsibility
  • News
  • Portfolio
  • Responsibility Report
  • Annual Reports
  • Leadership
  • Governance
  • SEC Filings

Latest Press Releases

August 22, 2023
Incyte to Present at Upcoming Investor Conferences
August 1, 2023
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
July 31, 2023
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
All press releases

Latest Events

Sep 14 2023 Sep 14 2023
Bank of America 2023 Global Healthcare Conference
Click here for Webcast
Sep 11 2023 Sep 11 2023
Morgan Stanley 21st Annual Global Healthcare Conference
Click here for Webcast
Sep 7 2023 Sep 7 2023
Wells Fargo 2023 Healthcare Conference
Click here for Webcast
All events
Market Cap:
Volume:
Sep 11, 2023 6:11 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Info
Show all

Q2 2023 RESULTS

  • Press Release
  • Presentation 1.6 MB
  • Webcast
  • Transcript 239 KB
All Quarterly Results

Investor Contacts

Greg Shertzer, PharmD

Director, Investor Relations

302.274.4779

gshertzer@incyte.com

Incyte Home © 2012-2023 Incyte.
  • Facebook Icon
  • LinkedIn Icon
  • Twitter Icon
  • Youtube Icon
  • Legal Notice
  • Privacy Policy
  • Cookie Policy
  • Suppliers
  • Site Map